Henry Jacob Conter
About
In The Last Decade
Henry Jacob Conter
43 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 1.7k
- Pulmonary and Respiratory Medicine 1.3k
- Immunology 341
- Surgery 197
- Cancer Research 152
Countries citing papers authored by Henry Jacob Conter
This map shows the geographic impact of Henry Jacob Conter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Jacob Conter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Jacob Conter more than expected).
Fields of papers citing papers by Henry Jacob Conter
This network shows the impact of papers produced by Henry Jacob Conter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Jacob Conter. The network helps show where Henry Jacob Conter may publish in the future.
Co-authorship network of co-authors of Henry Jacob Conter
This figure shows the co-authorship network connecting the top 25 collaborators of Henry Jacob Conter. A scholar is included among the top collaborators of Henry Jacob Conter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Jacob Conter. Henry Jacob Conter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 6 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | 3 | |
| 7 | 3 | |
| 8 | 5 | |
| 9 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial breakdown → | 405 |
| 10 | 25 | |
| 11 | 4 | |
| 12 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial breakdown → | 1137 |
| 13 | 15 | |
| 14 | 8 | |
| 15 | 1 | |
| 16 | 24 | |
| 17 | 1 | |
| 18 | 59 | |
| 19 | 73 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.